Valeo Pharma Inc. (VPHIF)
OTC PINK OTC PINK Primary 
Valeo Pharma adds chief development officer to drive growth initiatives
Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) announced that Al Moghaddam will be taking up the newly created role of chief development officer and, as a result will be stepping down from the company's board of directors. The Canadian pharmaceutical company said that as CDO, Moghaddam will lead the design and implementation of strategies to identify and negotiate with financial parties to strengthen its capital structure.
Valeo Pharma sees record 2Q revenue boosted by respiratory products and core brand growth
Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) saw revenue for the second quarter of 2024 increase primarily driven by successful promotional activities for respiratory products, increased sales of Allerject, and continued growth in other core products like Redesca and Simbrinza. In its 2Q financial statement, the Canadian pharmaceutical company posted revenues of $14.1 million, up 4% from $13.6 million in the same year-ago period.
Valeo Pharma restructures field operations to save over $5m annually
Valeo Pharma Inc said it has launched a restructuring of its field sales operations, taking cost-cutting to more than $7 million a year, including other recent measures. The latest initiative, which includes a 20% reduction of the workforce, aims to improve margins, reduce operating expenses, and accelerate the company's path to profitability.
